Reading the new retatrutide paper with my side-effect hat on

I read the full TRIUMPH-1 paper over coffee this morning, mostly because I wanted the actual adverse-event tables and not just the headline number. The triple-agonist mechanism is fascinating, and in the trials the weight-loss signal looks strong. But what I keep thinking about is tolerability: a drug can look great on average and still be a rough ride for the people who drop out early. I'm 11 months on tirzepatide, down 29 lbs, and my main win has been quieter food noise rather than a dramatic scale plunge. So I'm curious whether folks here care more about the average loss or the dropout/side-effect details when a new paper drops?